Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
3.
Med J Aust ; 193(1): 13-6, 2010 Jul 05.
Artigo em Inglês | MEDLINE | ID: mdl-20618107

RESUMO

OBJECTIVE: To determine the opinions and current practice of obstetricians and gynaecologists and trainees in the specialty with regard to induced abortion. DESIGN, SETTING AND PARTICIPANTS: A voluntary, anonymous survey of Australian Fellows and specialist trainees of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists was conducted between 23 June and 31 July 2009 using an email invitation to proceed to an online questionnaire. MAIN OUTCOME MEASURES: Attitudes to abortion; self-reported usual practice of induced abortion. RESULTS: Of 1498 Fellows and trainees invited to complete the questionnaire, 740 (49%) did so. Of these respondents, 632 (85%) stated that they did not hold religious or conscientious views that would make them totally opposed to abortion; 463 of these (73%) reported performing abortion as part of their personal practice, with 204 (44%) doing so only for severe fetal abnormality or serious maternal medical conditions. 108 respondents reported holding views that made them totally opposed to abortion - 60 (56%) opposed it in any situation at all and 48 (44%) opposed it with limited exceptions. Of those opposed, 34 (32%) added comment that they perform abortion for severe fetal abnormality or serious maternal medical conditions, and a further 17 (16%) commented that they refer women requesting abortion in these circumstances to colleagues. Of the respondents not opposed to abortion, 89% supported the availability of induced abortion within the public health system, and half felt that national availability of mifepristone would modify their practice of induced abortion. CONCLUSIONS: There was broad support among responding specialist obstetricians and gynaecologists and trainees for the availability of induced abortion in Australia. This study highlights the difficulties of accurately reporting a wide range of views on a contentious issue.


Assuntos
Aborto Induzido , Obstetrícia , Padrões de Prática Médica/estatística & dados numéricos , Aborto Induzido/estatística & dados numéricos , Austrália , Bolsas de Estudo , Feminino , Humanos , Sociedades Médicas
4.
Med J Aust ; 187(3): 171-3, 2007 Aug 06.
Artigo em Inglês | MEDLINE | ID: mdl-17680745

RESUMO

Mifepristone (RU486), which is used for early medical abortion, can only be obtained in Australia under the Authorised Prescriber legislation (Section 19[5] of the Therapeutic Goods Act 1989 [Cwlth]); two of the authors have permission to obtain, prescribe and administer this drug in Cairns, Queensland. From July 2006 to April 2007, 10 women who fulfilled the Therapeutic Goods Administration (TGA) criteria of "life-threatening or otherwise serious" indications underwent medical abortion with mifepristone/misoprostol, and 12 women conforming with abortion requirements of Queensland law, but not TGA legislation for mifepristone administration, had medical abortions with the less preferable methotrexate/misoprostol combination. Although it is now more than a year since the cross-party vote in federal Parliament in February 2006 confirmed wide support for the right of Australian women to a medical abortion, we believe we are at present the only medical practitioners in Australia with permission to use mifepristone. Obtaining Authorised Prescriber status from the TGA is of necessity a complex and protracted process, involving ethics committee approval and auditing, and regular reporting to the TGA. Because of the current restrictions, we believe that women seeking medical abortion in Australia face barriers not experienced by women in other comparable countries, and that drug manufacturing and distributing companies may be discouraged from seeking to market mifepristone in Australia.


Assuntos
Abortivos Esteroides , Aborto Terapêutico/estatística & dados numéricos , Controle de Medicamentos e Entorpecentes , Mifepristona , Prescrições de Medicamentos/estatística & dados numéricos , Feminino , Humanos , Gravidez , Queensland/epidemiologia
5.
Sex Health ; 4(4): 223-6, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18082063

RESUMO

Recent changes to Federal Therapeutic Goods Administration legislation have seen the limited introduction of the drug mifepristone to Australia for the purpose of early medical abortion. At the same time it has become evident that both methotrexate and misoprostol, licenced and available for other indications, are being used safely and appropriately for early abortion by Australian medical practitioners. Early medical abortion is widely practiced overseas where its safety and effectiveness are well supported by current evidence. However, abortion law in many states is still contained within the Criminal Codes and does not reflect current evidence-based abortion practice. In other states and territories restrictions on where abortions may be performed pose potential barriers to the introduction of mifepristone for medical abortion. There is an urgent need for abortion law to be clarified and made uniform across the country so that the best possible services can be provided to Australian women.


Assuntos
Abortivos Esteroides , Aborto Legal/legislação & jurisprudência , Serviços de Planejamento Familiar/legislação & jurisprudência , Legislação como Assunto , Mifepristona , Direitos da Mulher/legislação & jurisprudência , Austrália , Feminino , Regulamentação Governamental , Humanos , Gravidez , Primeiro Trimestre da Gravidez , Opinião Pública
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA